The FDA is helping to speed up the process of researching and approving psilocybin, a hallucinogenic substance super dry magic mushrooms in magic mushrooms, to treat major depressive disorder (MDD). An evaluation of the therapeutic value, benefits and risks of methylenedioxymethamphetamine (MDMA) and psilocybin for the treatment of mental, behavioural or developmental disorders. The study involved 51 individuals who underwent